Exclusive Interview with MYNT: Targeting the Global Market and Promoting Smoke-Free Nicotine Products

2Firsts Events by 2FIRSTS
Sep.07.2024
Exclusive Interview with MYNT: Targeting the Global Market and Promoting Smoke-Free Nicotine Products
MYNT CEO Shivam Bihani shares company's journey in nicotine pouch industry, focusing on innovation and global expansion.

On September 6th, Shivam Bihani, the founder and CEO of the Indian nicotine pouch brand MYNT, shared the company's development history, market layout, and future prospects in an interview with 2Firsts. Founded 75 years ago, MYNT has been focusing on research and development and export business of nicotine pouches since entering the oral tobacco market in 2019. The company is committed to improving product taste and user experience through technological innovation.

 

The pharmaceutical background supports the layout of the nicotine pouch market

 

The predecessor of MYNT was a pharmaceutical company, which in 2019 decided to focus its energy on the nicotine pouch field. Shivam Bihani pointed out that the company's pharmaceutical experience has provided a solid foundation for the production and quality control of nicotine pouches, which is also one of the key factors that allow MYNT products to meet the strict standards of the European and American markets. The company's products are currently mainly exported to the European and American markets, as the sale of nicotine pouch products is not allowed in India. The company is optimistic about the potential for global development in the future.

 

MYNT faces strict regulatory requirements for the export of nicotine pouches. Shivam Bihani mentioned that the company had to comply with the FDA's PMTA (Pre-Market Tobacco Product Application) requirements when entering the US market, which not only consumed a significant amount of time and money, but also posed challenges for the company's global expansion. In addition to the US, MYNT also needs to adhere to export qualification restrictions in other countries, further emphasizing the importance of global compliance in the nicotine pouch industry.

 

The company's focus is on the markets in the UK and Malaysia

 

MYNT's nicotine pouch products come in two packaging forms: pouches and boxes, to meet the needs of different consumers. Shivam Bihani emphasizes that through technological innovation, MYNT is able to provide consumers with a better taste experience, which is one of the company's core competitive advantages. Additionally, the company pays attention to the design of the packaging and has obtained relevant patents for protection.

 

Exclusive Interview with MYNT: Targeting the Global Market and Promoting Smoke-Free Nicotine Products
MYNT bagged products | Image source: 2Firsts

 

Exclusive Interview with MYNT: Targeting the Global Market and Promoting Smoke-Free Nicotine Products
MYNT box-packaged product | Image source: 2Firsts

 

During the exhibition in Malaysia, MYNT expressed a strong intention to develop global exports. Shivam Bihani revealed that the company's current focus is on the UK and Malaysian markets. He believes that as nicotine pouch products gradually become more popular worldwide, more nicotine users will be able to break the habit of smoking and reduce the health risks associated with traditional tobacco products.

 

Confidence in the Future of Nicotine Pouches

 

Shivam Bihani is confident in the future of nicotine pouches. He believes that despite being a new nicotine product like e-cigarettes, there are significant differences between the two in the market, they are very different. Nicotine pouches are becoming increasingly popular among global consumers due to their smoke-free and convenient characteristics, and they have huge market potential.

 

In regards to the company's development plan, Shivam Bihani stated that the company will continue to focus on the nicotine pouch sector and will not consider expanding into the chewing gum or other compressed product categories. In the future, they will continue to cultivate this market and provide high-quality, safe smokeless nicotine products for consumers worldwide.

 

MYNT's global strategy not only demonstrates the potential of Indian companies in the nicotine pouch field, but also provides new ideas for the global development of the nicotine pouch industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10